Skip to content

Author

T. Yau

We have 3 of 254 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Molecular Mechanisms of Therapeutic Resistance in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) remains a major global health burden, and therapeutic resistance continues to limit the benefit from systemic treatment. Despite advances in systemic therapies, including immune checkpoint inhibitor-based combinations, antiangiogenic agents, and multitargeted tyrosine kinase inhibitors fo...

K. Li, F. Sun, S. Chan et al. · 0 citations
Case report Open access Aug 2026

Case Report: Targeting EGFR exon 20 insertion and MTAP loss in refractory metastatic upper tract urothelial carcinoma

This case report illustrates the use of amivantamab in combination with pemetrexed-based chemotherapy for the treatment of a 60-year-old man with refractory metastatic upper tract urothelial carcinoma (UTUC) with epidermal growth factor receptor (EGFR) exon 20 insertion (D770_N771insGF) and methylthioadenosine phosphor...

K. Li, R. Leung, T. Yau et al. · 0 citations
Review Open access Sep 2026

Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: results from the CheckMate 459 phase III trial.

BACKGROUND & AIMS First-line nivolumab demonstrated a higher objective response rate (ORR) and favorable safety profile vs. sorafenib in advanced HCC in the phase 3 CheckMate 459 trial; however, no significant improvement in overall survival (OS) was observed. Here, we report exploratory biomarker analyses from CheckMa...

J. Neely, Jin Yao, M. Kudo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.